RNA Therapeutics: Antisense vs RNAi at $8.9B vs $27.5B

RNA therapeutics is an overlooked platform war in biotech. Two technologies, antisense oligonucleotides (ASO) and RNA interference (RNAi), both silence disease-causing genes. Both have approved drugs. Both have multi-billion-dollar market caps. But the gap between the two leaders has narrowed dramatically in the last 48 hours.

Ionis (IONS) trades at $8.85 billion market cap. Alnylam (ALNY) trades at $27.5 billion. On July 29, that gap was $8.93 billion versus $37 billion. Then Alnylam reported Q2 earnings on July 30, cut its TTR franchise guidance by $200 million at the midpoint, and the stock fell 29% in a single session. The RNAi leader lost $9.5 billion of market cap in one day. The antisense leader did not move. The platform valuation gap just compressed by more than half.

This roundup ranks the five RNA-therapeutic catalysts through Q1 2027 and asks whether antisense is finally closing the gap with RNAi.

Catalyst 1: Ionis zilganersen PDUFA (September 22, 2026)

Ionis has two FDA decisions in the next 60 days. The first is zilganersen for Alexander disease, a rare progressive neurological condition caused by mutations in the GFAP gene. The PDUFA date is September 22, 2026, with Priority Review and Breakthrough Therapy designation.

The registrational trial (NCT04849741) enrolled 54 patients across 13 sites in 8 countries. The primary endpoint was percent change in gait speed on the 10-Meter Walk Test. Zilganersen demonstrated a 33.3% mean difference in gait speed versus control at Week 61 (p=0.0412). Plasma GFAP levels decreased 33.6%, confirming target engagement. If approved, this would be the first disease-modifying therapy for Alexander disease, a condition with zero approved treatments.

The commercial opportunity is tiny. Alexander disease prevalence is roughly 1 in 2.7 million people, meaning approximately 500 diagnosed cases worldwide. At ultra-rare pricing of $300,000 to $2 million per patient annually, peak sales range from $150 million to $1 billion. This does not move Ionis’s $8.85 billion market cap. The value is platform validation: a zilganersen approval proves the antisense platform works in the central nervous system, opening the door to larger neurological indications. This thesis was covered in detail in the zilganersen platform analysis. The risk is low given Breakthrough Therapy, Priority Review, and no approved alternatives. The stock impact is modest.

Catalyst 2: Ionis bepirovirsen PDUFA (October 26, 2026)

The second Ionis decision is bepirovirsen for chronic hepatitis B, partnered with GSK. The PDUFA date is October 26, 2026, also with Priority Review and Breakthrough Therapy designation. This is the bigger catalyst.

The Phase 3 B-Well 1 and B-Well 2 trials enrolled over 1,800 patients across 29 countries. Results were published in the New England Journal of Medicine. Bepirovirsen achieved a functional cure rate of 20% in B-Well 1 (127 of 650 patients) and 19% in B-Well 2 (106 of 570 patients), versus 0% in placebo arms (p<0.001 in both trials). In patients with baseline HBsAg levels at or below 1,000 IU/mL, cure rates rose to 25% and 28%. The current standard of care, nucleos(t)ide analogues, achieves functional cure rates of approximately 1%.

Chronic hepatitis B affects 250 million people worldwide and causes 1.1 million deaths annually. If approved, bepirovirsen would be the first finite, six-month functional cure therapy. Ionis earns tiered royalties of 10 to 12% on net sales. At peak sales estimates of $2 to $4 billion, Ionis could collect $200 to $480 million in annual royalty revenue. That is meaningful for a company with $268 million in Q2 revenue. This is the highest-impact catalyst in the roundup. The risk: the NEJM editorial by Anna Lok flagged durability concerns and the exclusion of cirrhotic patients, which could mean a narrow label. But even a narrow label in HBsAg-low patients represents a first-in-class opportunity. More on Ionis earnings and pipeline in our Q2 analysis.

Catalyst 3: Alnylam zilebesiran hypertension Phase 3 (enrolling)

Alnylam’s zilebesiran is the RNAi platform’s attempt to break out of rare disease into a $50 billion plus hypertension market. The drug silences angiotensinogen in the liver, the most upstream target in the renin-angiotensin-aldosterone system. The Phase 2 KARDIA program is complete.

KARDIA-2 showed placebo-adjusted systolic blood pressure reductions of up to 12.1 mmHg at month 3 when zilebesiran was added to indapamide, 9.7 mmHg with amlodipine, and 4.0 mmHg with olmesartan. KARDIA-3, presented at ESC 2026, showed sustained reductions of at least 8 mmHg out to six months in patients uncontrolled on diuretics. Alnylam has advanced zilebesiran to a global Phase 3 cardiovascular outcomes trial called ZENITH, partnered with Roche.

The setup is promising but the timeline is long. A cardiovascular outcomes trial enrolls thousands of patients and runs for years. Data is not expected before 2029 at the earliest. At $27.5 billion market cap, Alnylam is not priced on zilebesiran. It is priced on the TTR franchise (AMVUTTRA, patisiran), which just hit $1 billion in quarterly revenue for the first time but also just had its guidance cut. The hypertension opportunity and the Alnylam zilebesiran KARDIA data were analyzed in a prior piece. The risk: Roche can walk away if interim data disappoints, and the hypertension market is crowded with generics.

Catalyst 4: Avidity delpacibart braxlosiran Phase 3 FORWARD (FSHD)

Avidity Biosciences (RNAM) is the wildcard. The company pioneered antibody-siRNA conjugates (AOCs), which attach RNAi payloads to antibodies that target the transferrin receptor 1 on muscle cells. This solves the delivery problem that has limited RNAi to liver-expressed targets. The lead asset is delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy (FSHD).

FSHD is a progressive muscle-wasting disease with zero approved therapies. The Phase 1/2 FORTITUDE trial showed greater than 50% mean reduction in DUX4-regulated genes at the 2 mg/kg every-six-weeks dose, with creatine kinase declining consistently in treated participants. On exploratory functional endpoints, del-brax treated participants improved relative to placebo on the 10-Meter Walk-Run, Timed Up-and-Go, and quantitative muscle testing at 12 months. The FDA confirmed an accelerated approval pathway is open, and Avidity has initiated the global Phase 3 FORWARD trial, an 18-month randomized placebo-controlled study. Novartis presented Phase 1/2 data at a June 2026 update showing the primary biomarker endpoint was met.

Avidity trades at approximately $11.24 billion market cap with only $19.6 million in Q1 revenue. That is a pre-revenue valuation for a company with one Phase 3 asset and two earlier-stage programs. The accelerated approval pathway means the FDA may accept biomarker data (DUX4-regulated gene suppression) rather than requiring a functional endpoint. If so, a BLA submission could come in late 2027. The risk: the FORTITUDE trial was not statistically powered for functional benefit, and the Phase 3 FORWARD trial must show clinical meaningfulness for full approval.

Catalyst 5: Arrowhead zodasiran Phase 3 YOSEMITE (data mid-2027)

Arrowhead Pharmaceuticals (ARWR) is the second RNAi platform company, smaller than Alnylam but with a deep cardiometabolic pipeline. Zodasiran targets ANGPTL3, a protein that inhibits triglyceride and cholesterol clearance. The Phase 3 YOSEMITE trial in homozygous familial hypercholesterolemia (HoFH) completed enrollment on July 27, 2026, with 70 patients. Data is expected in mid-2027.

Phase 2 data showed dose-dependent reductions in triglycerides and LDL-C. Arrowhead also has plozasiran targeting APOC3, which achieved mean max reductions of 90% in APOC3 and 87% in triglycerides in severe hypertriglyceridemia. Both drugs use Arrowhead’s TRiM RNAi platform.

Arrowhead trades at $12.3 billion market cap with $73.7 million in Q1 revenue. The P/S ratio is approximately 42x, by far the richest in the group. The YOSEMITE trial is in HoFH, a tiny indication (1 in 300,000 people). The real value is in broader dyslipidemia expansion. Enrollment completion is a milestone but data is a year away. The risk: Arrowhead has no approved drugs and is burning cash. YOSEMITE data in mid-2027 is the next material readout. See our YOSEMITE enrollment coverage for trial design details.

Risks

The RNA therapeutics sector carries platform-level risks. All four companies depend on oligonucleotide manufacturing at scale, which is capital-intensive and concentrated among a few contract manufacturers. A supply disruption affects the entire sector. Reimbursement for ultra-rare disease drugs is under increasing scrutiny from CMS and private payers. The Inflation Reduction Act’s drug price negotiation provisions could eventually reach RNA therapeutics, though most current drugs are too new to be included.

Alnylam’s guidance cut is a sector-level warning sign. If the leading RNAi franchise is seeing demand normalization in ATTR-CM, other RNA therapeutic launches may face similar adoption curves: an initial surge of second-line switchers followed by a slower first-line ramp. Ionis’s eplontersen failure in ATTR cardiomyopathy, detailed in the eplontersen Phase 3 failure analysis, is a reminder that RNA platform drugs fail too.

The verdict

Ranking by risk-reward over the next 12 months:

1. IONS bepirovirsen (Oct 26 PDUFA): Highest impact, binary but with strong Phase 3 data. The 20% functional cure rate in a 250 million-patient market is the biggest number in this roundup. Royalties of 10 to 12% on $2 to $4 billion peak sales is transformative for a $8.85 billion company. Buy ahead of the PDUFA, size for a 30% move either way.

2. IONS zilganersen (Sept 22 PDUFA): High probability of approval, low stock impact. The platform validation matters more than the revenue. A win here de-risks the bepirovirsen read eight weeks later.

3. ALNY zilebesiran (Phase 3 enrolling): Long timeline but massive TAM. The 29% stock crash has created a better entry point. At $27.5 billion, ALNY trades at approximately 5.9x forward revenue, cheaper than IONS at 8.3x. But the TTR guidance cut introduces execution risk.

4. RNAM del-brax (Phase 3 FORWARD): The technology is novel and the indication has zero competition. But $11.24 billion for a pre-revenue company with Phase 1/2 data is speculative. Wait for FORWARD interim data before sizing up.

5. ARWR zodasiran (YOSEMITE data mid-2027): The catalyst is a year out. At 42x P/S, the stock is priced for pipeline success that has not been demonstrated in Phase 3. The richest valuation in the group with the furthest catalyst.

The contrarian call: Ionis at $8.85 billion with two PDUFAs in 60 days is the best risk-reward in the RNA therapeutics sector. The antisense platform is about to get two FDA decisions that validate its applicability across neuroscience and infectious disease. Alnylam’s guidance cut has compressed the valuation gap from $28 billion to $19 billion. If both Ionis PDUFAs pass, the gap narrows further. For context on how priority review and rare disease pricing economics work, see our priority review voucher analysis.

Source: Ionis zilganersen press release | Bepirovirsen NEJM publication | Alnylam KARDIA-2 results